-
Mashup Score: 5
Copanlisib plus rituximab combination therapy for lymphoma reduces the risk of disease progression or death by 48%, recent data suggests
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Copanlisib plus rituximab improved progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma compared with placebo plus rituximab. To our knowledge, copanlisib is the first PI3K inhibitor to be safely combined with rituximab and the first to show broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Presenting at #AACR21: CHRONOS-3 #Copanlisib plus #rituximab vs placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma: a randomised, controlled, phase 3 trial #NonHodgkinLymphoma #lymsm https://t.co/wfjUQ7F27R
-
-
Mashup Score: 3New Drug Combination Helps People with Lymphoma - 3 year(s) ago
At the American Association for Cancer Research’s annual meeting, MSK medical oncologist Matthew Matasar presented results from a clinical trial for indolent B cell lymphoma that has relapsed after other treatments.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨#AACR21 Breaking News: New study finds that #copanlisib plus #rituximab resulted in a 48% reduction in the risk of disease progression or death vs placebo plus rituximab in patients with relapsed indolent non-Hodgkin #lymphoma (iNHL). @DrMatasar @AACR https://t.co/mfB2By1IUP
-
Check out the latest #AACR21 news demonstrating that #copanlisib #rituximab combination therapy reduces the risk of # lymphoma progression or death by 48% https://t.co/doT8fQzbXi